Comparison of disease progression subgroups in idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 6 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with an unpredictable course. The aims of this study were to retrospectively re-evaluate a cohort of patients with IPF according to the 2011 international IPF guidelines and 1) to characterize the subgroups of patients when classified according to their observed survival times and 2) to evaluate whether Composite Physiologic Index (CPI), Gender-Age-Physiology (GAP) Index or clinical variables could predict mortality. METHODS: Retrospective data was collected and patients were classified into subgroups according to their observed lifespans. Differences in clinical variables, CPI and GAP stages as well as in comorbidities were investigated between the subgroups. Predictors of mortality were identified by COX proportional hazard analyses. RESULTS: A total of 132 patients were included in this study. The disease course was rapid (≤ 2 years) in 30.0%, moderate (2-5 years) in 28.0% and slow (≥ 5 years) in 29.0% of the patients. Pulmonary function tests (PFT) and CPI at baseline differentiated significantly between the rapid disease course group and those patients with longer survival times. However, the predictive accuracy of the investigated clinical variables was mainly less than 0.80. The proportions of patients with comorbidities did not differ between the subgroups, but more patients with a rapid disease course were diagnosed with heart failure after the diagnosis of IPF. Most patients with a rapid disease course were categorized in GAP stages I and II, but all patients in GAP stage III had a rapid disease course. The best predictive multivariable model included age, gender and CPI. GAP staging had slightly better accuracy (0.67) than CPI (0.64) in predicting 2-year mortality. CONCLUSIONS: Although the patients with a rapid disease course could be differentiated at baseline in terms of PFT and CPI, the predictive accuracy of any single clinical variable as well as CPI and GAP remained low. GAP staging was unable to identify the majority of patients with a rapid disease progression. It is challenging to predict disease progression and mortality in IPF even with risk prediction models.
Overview
CoChat Summary
TL;DR
This retrospective cohort study of 132 patients with idiopathic pulmonary fibrosis (IPF) found that patients with rapid progression could be distinguished at baseline by pulmonary function and Composite Physiologic Index (CPI), but prediction of mortality remained poor overall. GAP staging was slightly better than CPI for 2-year mortality (0.67 vs 0.64), yet it still missed most rapid progressors.
Key findings
- Among 132 included patients, disease course was rapid in 40 (30.3%), moderate in 37 (28.0%), and slow in 39 (29.5%); median survival was 42 months.
- Baseline DLco % and CPI differed significantly between rapid progressors and the slower groups, but the predictive accuracy of investigated clinical variables was generally less than 0.80.
- GAP staging identified all 12 patients in GAP stage III as rapid progressors, but 23 of 40 rapid progressors were in GAP stages I or II; 40% of rapid progressors were in GAP stage II and 25% in stage I.
- For 2-year mortality, GAP had slightly better accuracy than CPI (0.67 vs 0.64); the best multivariable model included age, gender, and CPI.
Methods
- Retrospective cohort study at Kuopio University Hospital using medical records from 2002–2012; patients were re-evaluated under 2011 international IPF diagnostic guidelines.
- Initial evaluation included 223 patients with pulmonary fibrosis; 132 patients with IPF were included after excluding non-IPF diagnoses.
- Patients were grouped by observed survival after diagnosis: rapid (<2 years), moderate (2–5 years), and slow (>5 years); analyses used group comparisons, Kaplan-Meier/log-rank survival analysis, ROC curve analysis, and Cox proportional hazards models.
Limitations
- The paper states the study was relatively small and retrospectively collected.
- It notes possible selection/coding issues: some IPF patients may have been missed due to hospital register coding, and some frail patients may never have received diagnostic procedures, so IPF may not have been established.
- There was missing information, including spirometry results from 6 cases, preventing GAP stage calculation for those patients.
- Evident from the text: the cohort spans 2002–2012, during which IPF diagnostic criteria changed, although the authors re-assessed cases using 2011 criteria.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
4 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In our study cohort patients with a rapid disease course used more allopurinol, but allopurinol has not been related to increased risk of death in IPF [15, 29].”
§ Comparison of disease progression subgroups in idiopathic pulmonary fibrosis > Discussion
What the sources say
- Supportedcites [15] Karkkainen M, Kettunen HP, Nurmi H, Selander T, Purokivi M, Kaarteenaho R. Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):160. source
The citation supports the second clause of the sentence, not the citing authors’ observation about their own cohort’s rapid disease course. In Results > Comorbidities and medications (Table 5; page not provided), allopurinol use was not significantly associated with mortality in IPF; only four patients used it. (LLM, conf=0.89)
- Could not verifycites [29] Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med. 2009;103(6):927–31. sourceExperimental — accuracy not yet measured
Our copy of Gribbin et al. (2009) is a THIN case–control study of exposures recorded BEFORE the first IPF diagnosis; it contains no analysis of disease course, rapid progression, survival or any subgroup by outcome (searched: 'rapid disease course', 'survival/progression', 'mortality risk of death'). Allopurinol appears only as one pre-diagnosis exposure: Table 2 (20/920 cases, 2%, vs 92/3593 controls, 3%; OR 0.84, 95% CI 0.52–1.38, p = 0.493), and the Results state the odds ratios for gout and allopurinol 'were close to 1 and were not significant at the 5% level'. So the paper neither reports nor contradicts the citing authors' own cohort observation that rapid-course patients used more allopurinol; that point is outside this source's scope. (LLM, conf=0.68)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the predictive accuracy of the investigated clinical variables was mainly less than 0.80.”
- Also stated in: § Clinical factors in mortality prediction · plain
“In other variables, the predictive accuracy was less than 0.80.”
§ Comparison of disease progression subgroups in idiopathic pulmonary fibrosis > Abstract > Results
plainn = 132- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Clinical factors in mortality prediction · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas patients with slow disease course were more likely to suffer from asthma (26.7%) than patients with a more rapid course of disease (11.0%, p = 0.043)”
§ Comparison of disease progression subgroups in idiopathic pulmonary fibrosis > Results > Course of disease
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients with a rapid disease course had less lung cancer (0%) than patients with a moderate disease course (14.3%, p = 0.026)”
§ Comparison of disease progression subgroups in idiopathic pulmonary fibrosis > Results > Course of disease
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, there were fewer current smokers in the rapid disease course group than in the moderate group.”
§ Comparison of disease progression subgroups in idiopathic pulmonary fibrosis > Results > Course of disease
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
34 more claims
Create a free account to see all 62 claims and every source verdict.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 16
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The disease course was rapid (≤ 2 years) in 30.0%, moderate (2–5 years) in 28.0% and slow (≥ 5 years) in 29.0% of the patients.”
§ Comparison of disease progression subgroups in idiopathic pulmonary fibrosis > Abstract > Results
Reported 29 · recomputed 29.545455
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Wells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686
Chronic Bronchitis and Chronic Obstructive Pulmonary Disease
Kim, V., & Criner, G. J. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201210-1843ci · Cited by 513
Jacob, J., Bartholmai, B. J., Rajagopalan, S., Kokosi, M., Nair, A., Karwoski, R., Walsh, S. L. F., Wells, A. U., & Hansell, D. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01011-2016 · Cited by 309 · cited 1×
“[11] Stratification for CT algorithm and GAP/CPI CPI estimated severity of ILD better than GAP.”
BackgroundSpirometric Studies in Non-Smoking, Healthy Adults
Viljanen, A. A., Halttunen, P. K., Kreus, K.-E., & Viljanen, B. C. (1982) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365518209168377 · Cited by 237
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Mura, M., Porretta, M. A., Bargagli, E., Sergiacomi, G., Zompatori, M., Sverzellati, N., Taglieri, A., Mezzasalma, F., Rottoli, P., Saltini, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00106011 · Cited by 225
Natural history of idiopathic pulmonary fibrosis
Kim, H. J., Perlman, D., & Tomic, R. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.02.002 · Cited by 191
How does comorbidity influence survival in idiopathic pulmonary fibrosis?
Hyldgaard, C., Hilberg, O., & Bendstrup, E. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.01.008 · Cited by 180 · cited 1×
“reported that the diagnosis of any CVD after the diagnosis of IPF was related to a poorer prognosis [30].”
Background
Cited by
Huang, Y., Deng, J., Tian, Y., Liang, J., Xie, X. S., Huang, Y., Zhu, J., Zhu, Z., Zhou, Q., He, X., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01085 · Cited by 52
Chandel, A., Pastré, J., Valéry, S., King, C. S., & Nathan, S. D. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-218440 · Cited by 39
Karuga, F. F., Kaczmarski, P., Szmyd, B. M., Białasiewicz, P., Sochal, M., & Gabryelska, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175008 · Cited by 28
Montesi, S. B., Cosgrove, G. P., Turner, S., Zhou, I. Y., Efthimiou, N., Šušnjar, A., Catana, C., Fromson, C., Clark, A., Decaris, M. L., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202410-1934oc · Cited by 31
A modified GAP model for East-Asian populations with idiopathic pulmonary fibrosis
Nishikiori, H., Chiba, H., Lee, S. H., Kondoh, S., Kamo, K., Nakamura, K., Ikeda, K., Kuronuma, K., Chung, M. P., Kondoh, Y., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.04.001 · Cited by 22
Metadata
- Authors
- Kärkkäinen, M., Kettunen, H.-P., Nurmi, H., Selander, T., Purokivi, M., & Kaarteenaho, R.
- Affiliations
- University of Eastern Finland (FI)
- Kuopio University Hospital (FI)
- Oulu University Hospital (FI)
- Corresponding author
- Kärkkäinen, Miia
- Venue
- BMC Pulmonary Medicine
- Published
- 2019-11-29
- Volume
- 19
- Issue
- 1
- Pages
- 228-228
- ISSN
- 1471-2466 (ISSN-L)
- PMC
- PMC6883511
- OpenAlex
- W2990821151
- Cited by
- 23
- References
- 30
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 8 · 2021: 5 · 2020: 3
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- BMC Pulmonary Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Suomen Tuberkuloosin Vastustamisyhdistyksen Säätiö (None)
- The Organization for Respiratory Health in Finland (None)
- Väinö and Laina Kivi Foundation (None)
- The Kuopio Region Respiratory Foundation (None)
- Jalmari and Rauha Ahokas Foundation (None)
- Center of Medicine and Clinical Research in Kuopio University Hospital (None)
- the North Savo Regional Fund of the Finnish Cultural Foundation (None)
- the state subsidy of the Kuopio University Hospital (None)
- Research Director of Kuopio University Hospital (None)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, disease progression, mortality prediction, composite physiologic index, pulmonary function tests, risk stratification, heart failure, comorbidities, prognostic factors
- MeSH terms
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Retrospective Studies, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of disease progression subgroups in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12890-019-0996-2
- The paper
- Kärkkäinen, M., Kettunen, H.-P., Nurmi, H., Selander, T., Purokivi, M., & Kaarteenaho, R. (2019). Comparison of disease progression subgroups in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-019-0996-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.